Comment on “Daratumumab, lenalidomide, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma: A real-world propensity score-matched study”
Shobana ChandrasekarDepartment of Biochemistry, School of Life Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamil Nadu, India. Electronic address: [email protected]M.K. Rohith KrishnanDepartment of Anatomy, Fergana Medical Institute of Public Health, Yangituron Street 2A, Fergana, 150100, Uzbekistan. Electronic address: [email protected]Umesh KumarDepartment of Pharmacy- IBMER, Mangalaytan University, Aligarh, Uttar Pradesh, India. Electronic address: [email protected]
ABI
Аннотация
Аннотация мавжуд эмас.
Мавзулар
Идентификаторлар
Иқтибослар ва манбалар
0 та иқтибос2 та фойдаланилган манба